{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:53:29Z","timestamp":1791219209206,"version":"4.1.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2005,11,1]],"date-time":"2005-11-01T00:00:00Z","timestamp":1130803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T00:00:00Z","timestamp":1475798400000},"content-version":"vor","delay-in-days":3993,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2005,11]]},"DOI":"10.1016\/j.ymthe.2005.04.024","type":"journal-article","created":{"date-parts":[[2005,7,7]],"date-time":"2005-07-07T15:24:27Z","timestamp":1120749867000},"page":"876-884","source":"Crossref","is-referenced-by-count":157,"title":["Evasion of Immune Responses to Introduced Human Acid \u03b1-Glucosidase by Liver-Restricted Expression in Glycogen Storage Disease Type II"],"prefix":"10.1016","volume":"12","author":[{"given":"Luis M.","family":"Franco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baodong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Bird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayn","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talmage","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah P.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy M.","family":"Clay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Amalfitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.T.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dwight D.","family":"Koeberl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2005.04.024_bib1","series-title":"The Metabolic and Molecular Basis for Inherited Disease","first-page":"3389","author":"Hirschhorn","year":"2001"},{"key":"10.1016\/j.ymthe.2005.04.024_bib2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1089\/dna.1990.9.85","article-title":"Sequence of the cDNA and 5\u2032-flanking region for human acid alpha-glucosidase, detection of an intron in the 5\u2032 untranslated leader sequence, definition of 18-bp polymorphisms, and differences with previous cDNA and amino acid sequences","volume":"9","author":"Martiniuk","year":"1990","journal-title":"DNA Cell Biol."},{"key":"10.1016\/j.ymthe.2005.04.024_bib3","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1042\/bj2720493","article-title":"Characterization of the human lysosomal alpha-glucosidase gene","volume":"272","author":"Hoefsloot","year":"1990","journal-title":"Biochem. J."},{"key":"10.1016\/j.ymthe.2005.04.024_bib4","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S0002-9440(10)65361-8","article-title":"Murine acid alpha-glucosidase: cell-specific mRNA differential expression during development and maturation","volume":"154","author":"Ponce","year":"1999","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ymthe.2005.04.024_bib5","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0021-9258(18)53985-5","article-title":"Structural and functional-changes of lysosomal acid alpha-glucosidase during intracellular-transport and maturation","volume":"268","author":"Wisselaar","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymthe.2005.04.024_bib6","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1073\/pnas.93.1.65","article-title":"High-level production of recombinant human lysosomal acid alpha-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease","volume":"93","author":"Van Hove","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2005.04.024_bib7","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1172\/JCI1722","article-title":"Clinical and metabolic correction of Pompe disease by enzyme therapy in acid maltase-deficient quail","volume":"101","author":"Kikuchi","year":"1998","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2005.04.024_bib8","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1093\/hmg\/8.12.2145","article-title":"Human acid alpha-glucosidase from rabbit milk has therapeutic effect in mice with glycogen storage disease type II","volume":"8","author":"Bijvoet","year":"1999","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2005.04.024_bib9","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1006\/bbrc.2000.3555","article-title":"Correction of glycogen storage disease type II by enzyme replacement with a recombinant human acid maltase produced by over-expression in a CHO-DHFR(neg) cell line","volume":"276","author":"Martiniuk","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ymthe.2005.04.024_bib10","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ymgme.2003.08.022","article-title":"Enzyme replacement therapy in the mouse model of Pompe disease","volume":"80","author":"Raben","year":"2003","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2005.04.024_bib11","first-page":"132","article-title":"Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I\/II clinical trial","volume":"3","author":"Amalfitano","year":"2001","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymthe.2005.04.024_bib12","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1006\/mgme.1999.2894","article-title":"Immune response to enzyme replacement therapy in lysosomal storage disorder patients and animal models","volume":"68","author":"Brooks","year":"1999","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2005.04.024_bib13","doi-asserted-by":"crossref","first-page":"8861","DOI":"10.1073\/pnas.96.16.8861","article-title":"Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase","volume":"96","author":"Amalfitano","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2005.04.024_bib14","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1089\/104303401300042447","article-title":"Intercellular transfer of the virally derived precursor form of acid alpha-glucosidase corrects the enzyme deficiency in inherited cardioskeletal myopathy Pompe disease","volume":"12","author":"Pauly","year":"2001","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2005.04.024_bib15","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1089\/104303401750195917","article-title":"Long-term efficacy after [E1\u2212, polymerase\u2212] adenovirus-mediated transfer of human acid-alpha-glucosidase gene into glycogen storage disease type II knockout mice","volume":"12","author":"Ding","year":"2001","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2005.04.024_bib16","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1006\/mthe.2002.0563","article-title":"Efficacy of gene therapy for a prototypical lysosomal storage disease (GSD-II) is critically dependent on vector dose, transgene promoter, and the tissues targeted for vector transduction","volume":"5","author":"Ding","year":"2002","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2005.04.024_bib17","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1038\/sj.gt.3302314","article-title":"Improved efficacy of gene therapy approaches for Pompe disease using a new, immune-deficient GSD-II mouse model","volume":"11","author":"Xu","year":"2004","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2005.04.024_bib18","first-page":"357","article-title":"Adeno-associated virus vectors for gene therapy","volume":"2","author":"Flotte","year":"1995","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2005.04.024_bib19","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1006\/mthe.2002.0580","article-title":"Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors","volume":"5","author":"Fraites","year":"2002","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2005.04.024_bib20","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S1525-0016(03)00022-4","article-title":"Packaging of an AAV vector encoding human acid alpha-glucosidase for gene therapy in glycogen storage disease type II with a modified hybrid adenovirus\u2013AAV vector","volume":"7","author":"Sun","year":"2003","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2005.04.024_bib21","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S1525-0016(02)00055-2","article-title":"Long-term correction of glycogen storage disease type II with a hybrid Ad\u2013AAV vector","volume":"7","author":"Sun","year":"2003","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2005.04.024_bib22","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1089\/hum.2005.16.68","article-title":"Impact of humoral immune response on distribution and efficacy of recombinant adeno-associated virus-derived acid alpha-glucosidase in a model of glycogen storage disease type II","volume":"16","author":"Cresawn","year":"2005","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2005.04.024_bib23","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1182\/blood-2003-01-0222","article-title":"Phenotypic correction of a mouse model of hemophilia A using AAV2 vectors encoding the heavy and light chains of FVIII","volume":"102","author":"Scallan","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2005.04.024_bib24","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1182\/blood-2003-08-2954","article-title":"Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype","volume":"103","author":"Sarkar","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2005.04.024_bib25","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1073\/pnas.96.7.3906","article-title":"Sustained correction of bleeding disorder in hemophilia B mice by gene therapy","volume":"96","author":"Wang","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2005.04.024_bib26","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ymthe.2003.11.015","article-title":"AAV2 vector harboring a liver-restricted promoter facilitates sustained expression of therapeutic levels of alpha-galactosidase A and the induction of immune tolerance in Fabry mice","volume":"9","author":"Ziegler","year":"2004","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2005.04.024_bib27","doi-asserted-by":"crossref","first-page":"11854","DOI":"10.1073\/pnas.182412299","article-title":"Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy","volume":"99","author":"Gao","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2005.04.024_bib28","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ymthe.2004.10.004","article-title":"Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II","volume":"11","author":"Sun","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2005.04.024_bib29","doi-asserted-by":"crossref","first-page":"S329","DOI":"10.1016\/j.ymthe.2004.06.774","article-title":"Correction of glycogen storage disease type II by intramuscular administration of an adeno-associated virus 6 (AAV2\/6) vector containing a muscle-specific promoter","volume":"9","author":"Zhang","year":"2004","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2005.04.024_bib30","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1365-2362.1974.tb02358.x","article-title":"Increased excretion of a glucose-containing tetrasaccharide in the urine of a patient with glycogen storage disease type II (Pompe's disease)","volume":"4","author":"Hallgren","year":"1974","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2005.04.024_bib31","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/bms.1200030202","article-title":"Quantitation of a urinary tetrasaccharide by gas chromatography and mass spectrometry","volume":"3","author":"Lennartson","year":"1976","journal-title":"Biomed. Mass Spectrom"},{"key":"10.1016\/j.ymthe.2005.04.024_bib32","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1093\/clinchem\/36.7.1381a","article-title":"Unique oligosaccharide (apparently glucotetrasaccharide) in urine of patients with glycogen storage diseases","volume":"36","author":"Oberholzer","year":"1990","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ymthe.2005.04.024_bib33","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1006\/abio.2000.4838","article-title":"Liquid chromatographic assay for a glucose tetrasaccharide, a putative biomarker for the diagnosis of Pompe disease","volume":"287","author":"An","year":"2000","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ymthe.2005.04.024_bib34","first-page":"S23","article-title":"Optimization of the human factor VIII complementary DNA expression plasmid for gene therapy of hemophilia A","volume":"8","author":"Ill","year":"1997","journal-title":"Blood Coag. Fibrinol."},{"key":"10.1016\/j.ymthe.2005.04.024_bib35","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/13518","article-title":"Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors","volume":"5","author":"Snyder","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2005.04.024_bib36","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1182\/blood.V99.8.2670","article-title":"Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy","volume":"99","author":"Mount","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2005.04.024_bib37","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1172\/JCI200316887","article-title":"Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer","volume":"111","author":"Mingozzi","year":"2003","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2005.04.024_bib38","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1034\/j.1600-0528.2002.017408.x","article-title":"Local control of the immune response in the liver","volume":"174","author":"Knolle","year":"2000","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ymthe.2005.04.024_bib39","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1038\/sj.gt.3301829","article-title":"Adeno-associated virus vector-mediated gene transfer into dystrophin-deficient skeletal muscles evokes enhanced immune response against the transgene product","volume":"9","author":"Yuasa","year":"2002","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2005.04.024_bib40","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1089\/10430349950016942","article-title":"Enhanced expression of transgenes from adeno-associated virus vectors with the woodchuck hepatitis virus posttranscriptional regulatory element: implications for gene therapy","volume":"10","author":"Loeb","year":"1999","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2005.04.024_bib41","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1089\/104303401750061267","article-title":"Muscle-specific promoters may be necessary for adeno-associated virus-mediated gene transfer in the treatment of muscular dystrophies","volume":"12","author":"Cordier","year":"2001","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2005.04.024_bib42","doi-asserted-by":"crossref","first-page":"E448","DOI":"10.1542\/peds.113.5.e448","article-title":"Long term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk","volume":"113","author":"Van den Hout","year":"2004","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymthe.2005.04.024_bib43","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1093\/hmg\/10.19.2039","article-title":"Conditional tissue-specific expression of the acid alpha-glucosidase (GAA) gene in the GAA knockout mice: implications for therapy","volume":"10","author":"Raben","year":"2001","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2005.04.024_bib44","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1023\/A:1022998010833","article-title":"Induction of tolerance to a recombinant human enzyme, acid alpha-glucosidase, in enzyme deficient knockout mice","volume":"12","author":"Raben","year":"2003","journal-title":"Transgenic Res."},{"key":"10.1016\/j.ymthe.2005.04.024_bib45","doi-asserted-by":"crossref","first-page":"19086","DOI":"10.1074\/jbc.273.30.19086","article-title":"Targeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II","volume":"273","author":"Raben","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymthe.2005.04.024_bib46","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1172\/JCI1722","article-title":"Clinical and metabolic correction of Pompe disease by enzyme therapy in acid maltase-deficient quail","volume":"101","author":"Kikuchi","year":"1998","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2005.04.024_bib47","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0003-2697(03)00056-3","article-title":"Analysis of a glucose tetrasaccharide elevated in Pompe disease by stable isotope dilution\u2013electrospray ionization tandem mass spectrometry","volume":"316","author":"Young","year":"2003","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ymthe.2005.04.024_bib48","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/00002371-200501000-00008","article-title":"Enumerating antigen-specific T-cell responses in peripheral blood\u2014a comparison of peptide MHC tetramer, ELISpot, and intracellular cytokine analysis","volume":"28","author":"Hobeika","year":"2005","journal-title":"J. Immunother."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001605002315?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001605002315?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T04:41:24Z","timestamp":1626151284000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001605002315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,11]]}},"alternative-id":["S1525001605002315"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2005.04.024","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2005,11]]}}}